Methods for detecting hepatocellular carcinoma
AssigneesThe Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.
InventorsMei-Sze Chua, Samuel So, Hongbo Sun, Dan-Hui Dorothy Yang, Anya Tsalenko, Brian Jon Peter
Life of this patent
Estimating the term…
Abstract
A method for evaluating hepatocellular carcinoma in a subject is provided. In certain embodiments, the method comprises: a) obtaining a hepatocellular carcinoma protein marker profile for a sample obtained from the subject; and b) comparing the protein marker profile to a control profile.
Claims15
A method of distinguishing hepatocellular carcinoma (HCC) from viral induced cirrhosis in a subject, comprising:
- a) measuring levels of at least three HCC markers selected from one or both of a first group (i) and a second group (ii) of markers in a biological sample from said subject to obtain a hepatocellular carcinoma marker profile from said subject;
- b) comparing said marker profile to a control profile obtained from a viral-induced cirrhosis control sample, wherein differential expression of the at least three HCC markers in said biological sample compared to the control sample indicates a diagnosis of hepatocellular carcinoma in said subject;
- and wherein
- c) said differential expression comprises decreased expression in said first group of HCC markers and increased expression in said second group of HCC markers, and wherein
- d) said first group (i) consists of L-Selectin, IGFBP-6, IL-6sR, VCAM-1, FGF-basic, Fractalkine/CX3CL1, IL18;
- and
- e) said second group (ii) consists of β-Catenin, M-CSF, IL-8, MMP-10, Total p21, IL-1 ra, Resistin, interferon-gamma, BRAK/CXCL14, TNF-beta.
A method of distinguishing hepatocellular carcinoma (HCC) from viral induced cirrhosis in a subject, comprising:
- a) measuring levels of at least one HCC marker selected from the group consisting of M-CSF and MMP-10 in a biological sample from said subject to obtain a hepatocellular carcinoma marker profile from said subject;
- b) comparing said marker profile to a control profile obtained from a viral-induced cirrhosis control sample, wherein increased expression of the at least one HCC marker in said biological sample compared to the control profile indicates a diagnosis of hepatocellular carcinoma in said subject.
Dependencies are inferred from the claim text.